# Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia

> **NCT05203055** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fuzhou General Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Chronic Hepatitis B Patients With a Normal ALT Level and Low Viremia

## Interventions

- **DRUG:** Peginterferon alpha-2b
- **DRUG:** Nucleotide Analog
- **DRUG:** pulse peginterferon alpha-2b

## Key facts

- **NCT ID:** NCT05203055
- **Lead sponsor:** Fuzhou General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-10
- **Primary completion:** 2022-12-10
- **Final completion:** 2023-12-10
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05203055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05203055, "Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low Viremia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05203055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*